Immune modulators in allergic airway inflammation

Devendra K. Agrawal, M. T. Hopfenspirger, J. Edwan

Research output: Contribution to journalReview article

Abstract

Immune modulators can shape the host response to challenge with innocuous antigens and protect against allergic airway inflammation in asthma and possibly other allergic diseases. Among several potential modulators, Flt3-ligand is a novel agent, which prevented and reversed LAR, AHR, and eosinophilia in a murine asthma model. Flt3-ligand induces the generation and peripheral scattering of dendritic cells with preferential expansion of CD8α+ and IL-12 producing dendritic cells. Additionally, Flt3-ligand may also enhance CD4 +CD25+ regulatory T cells in the lungs. Flt3-ligand may prove to be a novel adjuvant therapy in bronchial asthma. In view of numerous immune cells and mediators that contribute to the exacerbations and progress of asthma, it is not surprising that there are likewise numerous potential modalities to treat the disease. Since the dynamic of the TH1/ T H2 phenotype as it relates to allergy and asthma has become more fully appreciated, studies have been focused to modulate this balance with the goal of suppressing type 2 responses (1,2). Largely, these efforts have focused on stimulating antigen-specific TH1 responses, as the T-helper subsets have been shown to be polarizing and mutually antagonistic in nature (3). This article focuses primarily on the strategies and approaches that have been attempted to develop novel and effective therapy of asthma by modulating the immune response.

Original languageEnglish
Pages (from-to)19-23
Number of pages5
JournalModern Aspects of Immunobiology
Volume15
StatePublished - 2005

Fingerprint

Asthma
Inflammation
Dendritic Cells
Antigens
Eosinophilia
Regulatory T-Lymphocytes
Interleukin-12
Hypersensitivity
Phenotype
Lung
flt3 ligand protein
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology

Cite this

Immune modulators in allergic airway inflammation. / Agrawal, Devendra K.; Hopfenspirger, M. T.; Edwan, J.

In: Modern Aspects of Immunobiology, Vol. 15, 2005, p. 19-23.

Research output: Contribution to journalReview article

Agrawal, DK, Hopfenspirger, MT & Edwan, J 2005, 'Immune modulators in allergic airway inflammation', Modern Aspects of Immunobiology, vol. 15, pp. 19-23.
Agrawal, Devendra K. ; Hopfenspirger, M. T. ; Edwan, J. / Immune modulators in allergic airway inflammation. In: Modern Aspects of Immunobiology. 2005 ; Vol. 15. pp. 19-23.
@article{a2ba816a84744462bdfef037f48cee39,
title = "Immune modulators in allergic airway inflammation",
abstract = "Immune modulators can shape the host response to challenge with innocuous antigens and protect against allergic airway inflammation in asthma and possibly other allergic diseases. Among several potential modulators, Flt3-ligand is a novel agent, which prevented and reversed LAR, AHR, and eosinophilia in a murine asthma model. Flt3-ligand induces the generation and peripheral scattering of dendritic cells with preferential expansion of CD8α+ and IL-12 producing dendritic cells. Additionally, Flt3-ligand may also enhance CD4 +CD25+ regulatory T cells in the lungs. Flt3-ligand may prove to be a novel adjuvant therapy in bronchial asthma. In view of numerous immune cells and mediators that contribute to the exacerbations and progress of asthma, it is not surprising that there are likewise numerous potential modalities to treat the disease. Since the dynamic of the TH1/ T H2 phenotype as it relates to allergy and asthma has become more fully appreciated, studies have been focused to modulate this balance with the goal of suppressing type 2 responses (1,2). Largely, these efforts have focused on stimulating antigen-specific TH1 responses, as the T-helper subsets have been shown to be polarizing and mutually antagonistic in nature (3). This article focuses primarily on the strategies and approaches that have been attempted to develop novel and effective therapy of asthma by modulating the immune response.",
author = "Agrawal, {Devendra K.} and Hopfenspirger, {M. T.} and J. Edwan",
year = "2005",
language = "English",
volume = "15",
pages = "19--23",
journal = "Modern Aspects of Immunobiology",

}

TY - JOUR

T1 - Immune modulators in allergic airway inflammation

AU - Agrawal, Devendra K.

AU - Hopfenspirger, M. T.

AU - Edwan, J.

PY - 2005

Y1 - 2005

N2 - Immune modulators can shape the host response to challenge with innocuous antigens and protect against allergic airway inflammation in asthma and possibly other allergic diseases. Among several potential modulators, Flt3-ligand is a novel agent, which prevented and reversed LAR, AHR, and eosinophilia in a murine asthma model. Flt3-ligand induces the generation and peripheral scattering of dendritic cells with preferential expansion of CD8α+ and IL-12 producing dendritic cells. Additionally, Flt3-ligand may also enhance CD4 +CD25+ regulatory T cells in the lungs. Flt3-ligand may prove to be a novel adjuvant therapy in bronchial asthma. In view of numerous immune cells and mediators that contribute to the exacerbations and progress of asthma, it is not surprising that there are likewise numerous potential modalities to treat the disease. Since the dynamic of the TH1/ T H2 phenotype as it relates to allergy and asthma has become more fully appreciated, studies have been focused to modulate this balance with the goal of suppressing type 2 responses (1,2). Largely, these efforts have focused on stimulating antigen-specific TH1 responses, as the T-helper subsets have been shown to be polarizing and mutually antagonistic in nature (3). This article focuses primarily on the strategies and approaches that have been attempted to develop novel and effective therapy of asthma by modulating the immune response.

AB - Immune modulators can shape the host response to challenge with innocuous antigens and protect against allergic airway inflammation in asthma and possibly other allergic diseases. Among several potential modulators, Flt3-ligand is a novel agent, which prevented and reversed LAR, AHR, and eosinophilia in a murine asthma model. Flt3-ligand induces the generation and peripheral scattering of dendritic cells with preferential expansion of CD8α+ and IL-12 producing dendritic cells. Additionally, Flt3-ligand may also enhance CD4 +CD25+ regulatory T cells in the lungs. Flt3-ligand may prove to be a novel adjuvant therapy in bronchial asthma. In view of numerous immune cells and mediators that contribute to the exacerbations and progress of asthma, it is not surprising that there are likewise numerous potential modalities to treat the disease. Since the dynamic of the TH1/ T H2 phenotype as it relates to allergy and asthma has become more fully appreciated, studies have been focused to modulate this balance with the goal of suppressing type 2 responses (1,2). Largely, these efforts have focused on stimulating antigen-specific TH1 responses, as the T-helper subsets have been shown to be polarizing and mutually antagonistic in nature (3). This article focuses primarily on the strategies and approaches that have been attempted to develop novel and effective therapy of asthma by modulating the immune response.

UR - http://www.scopus.com/inward/record.url?scp=49749109108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49749109108&partnerID=8YFLogxK

M3 - Review article

VL - 15

SP - 19

EP - 23

JO - Modern Aspects of Immunobiology

JF - Modern Aspects of Immunobiology

ER -